Bandhan BSE Healthcare Index Fund vs Tata India Pharma & Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
Bandhan BSE Healthcare Index Fund is an Index fund and Tata India Pharma & Healthcare Fund is a Thematic fund. In the year to 30-10-2026, Bandhan BSE Healthcare Index Fund (Direct) returned 12.0% and Tata India Pharma & Healthcare Fund (Direct) returned 4.3%. Bandhan BSE Healthcare Index Fund charges 0.34% a year and Tata India Pharma & Healthcare Fund 1.10% (Direct plans). Their portfolios overlap 53.9%: they hold 30 of the same securities.
Bandhan BSE Healthcare Index Fund
Index
- 1 year return
- 12.0%
- Expense ratio
- 0.34%
- NAV
- ₹11.58
Tata India Pharma & Healthcare Fund
Thematic
- 1 year return
- 4.3%
- Expense ratio
- 1.10%
- NAV
- ₹37.77
Which is better, Bandhan BSE Healthcare Index or Tata India Pharma & Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Bandhan BSE Healthcare Index returned more over 1 year: 12.0% against 4.3%.
- Bandhan BSE Healthcare Index costs less: 0.34% a year against 1.10% (Direct plans).
- Bandhan BSE Healthcare Index fell less in its worst fall since 09-09-2024: −16.2% against −16.8%.
- Tata India Pharma & Healthcare is the larger fund: ₹1,511 Cr against ₹21 Cr.
- Their portfolios overlap 53.9%: 30 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Bandhan BSE Healthcare Index Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Fund house | Bandhan Mutual Fund | Tata Mutual Fund |
| Category | Index | Thematic |
| AUM | ₹21 Cr (31-08-2026) | ₹1,511 Cr (30-09-2026) |
| NAV | ₹11.58 (Direct) | ₹37.77 (Direct) |
| Expense ratio (Direct) | 0.34% | 1.10% |
| Expense ratio (Regular) | 1.15% | 2.42% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 06-09-2024 | 28-12-2015 |
| Minimum investment | ₹1,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Abhishek Jain | Rajat Srivastava |
| Exit load | • 0.25% if redeemed on or before 15 days from the allotment date. • Nil if redeemed after 15 days from allotment date. | 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment. |
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Bandhan BSE Healthcare Index Fund (Direct) | +0.22% | −1.08% | +12.61% | +11.96% | -- | -- | -- |
| Tata India Pharma & Healthcare Fund (Direct) | −1.40% | −5.00% | +6.91% | +4.28% | +19.28% | +14.93% | +14.64% |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | +13.76% |
Category average: the average of the 235 Thematic funds, same plan type.
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: Year-wise Returns
| Year | Bandhan BSE Healthcare IndexBandhan BSE Healthcare Index | Tata India Pharma & HealthcareTata India Pharma & Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +14.73% | +6.77% | +15.08% |
| 2025 | −2.98% | −3.47% | −2.72% |
| 2024 | -- | +42.48% | +44.30% |
| 2023 | -- | +38.59% | +37.97% |
| 2022 | -- | −6.64% | −11.50% |
| 2021 | -- | +20.88% | +21.54% |
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 1-year holding period, 284 of them, one for each trading day from 09-09-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Bandhan BSE Healthcare Index Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
to
Oct 2025Dec 2024
to
Dec 2025Mar 2025
to
Mar 2026May 2025
to
May 2026Jul 2025
to
Jul 2026Sept 2025
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bandhan BSE Healthcare Index | 15.5 | 26.8 | 20.1 | 28.2 | 9.5 | 0.0 | 0.0 | 6.9% | 7.2% | −4.0% | 19.1% | 0% |
| Tata India Pharma & Healthcare | 18.6 | 30.0 | 35.7 | 15.7 | 0.0 | 0.0 | 0.0 | 5.1% | 5.5% | −3.9% | 14.9% | 14% |
| BSE Healthcare TRI | 14.4 | 26.1 | 19.7 | 28.2 | 11.6 | 0.0 | 0.0 | 7.3% | 7.5% | −3.7% | 19.5% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 09-09-2024. Past returns do not promise future returns.
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 09-09-2024 to 30-10-2026: 26 instalments, ₹2,60,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Bandhan BSE Healthcare IndexBandhan BSE Healthcare Index Fund (Direct) | ₹2,60,000 | ₹2,95,489 | ₹35,489 | 11.9% |
| Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct) | ₹2,60,000 | ₹2,77,567 | ₹17,567 | 6.0% |
Bandhan BSE Healthcare IndexBandhan BSE Healthcare Index Fund (Direct)
Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Bandhan BSE Healthcare Index Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +11.96% | +4.28% |
| Standard deviation | 13.61% | 11.99% |
| Sharpe ratio | 0.49 | -0.08 |
| Sortino ratio | 0.72 | -0.11 |
| Maximum drawdown | −10.0% (23-10-2026) | −11.0% (23-10-2026) |
| Beta | 1.00 | 0.82 |
| Alpha | −0.41% | −6.83% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Bandhan BSE Healthcare Index Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +7.26% | +13.01% |
| Standard deviation | 14.58% | 15.08% |
| Sharpe ratio | 0.11 | 0.50 |
| Sortino ratio | 0.15 | 0.72 |
| Maximum drawdown | −16.2% (28-02-2025) | −19.8% (21-08-2017) |
| Beta | 1.00 | 0.87 |
| Alpha | −0.33% | +2.53% |
From daily NAVs, 09-09-2024 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Bandhan BSE Healthcare Index Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Bandhan BSE Healthcare Index Fund (Direct) | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
| Tata India Pharma & Healthcare Fund (Direct) | −16.8% | 02-01-2025 | 28-02-2025 | 11-05-2026 | 14 months | −6.0% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 09-09-2024, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Bandhan BSE Healthcare Index Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund (Direct) | 99% | 101% | 0.04% |
| Tata India Pharma & Healthcare Fund (Direct) | 89% | 106% | 3.01% |
From month-end values since 09-09-2024. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Bandhan BSE Healthcare Index Fund, August 2026; Tata India Pharma & Healthcare Fund, September 2026
Holdings in common
- Overlap
- 53.9%
- Held by both
- 30
- Only in Bandhan BSE Healthcare Index
- 95
- Only in Tata India Pharma & Healthcare
- 11
| Security | % of Bandhan BSE Healthcare Index | % of Tata India Pharma & Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 12.95% | 7.99% |
| Divi's Laboratories Limited | 7.22% | 5.68% |
| Apollo Hospitals Enterprise Limited | 5.55% | 4.36% |
| Dr. Reddy's Laboratories Limited | 4.35% | 4.65% |
| Cipla Limited | 4.91% | 4.22% |
| Torrent Pharmaceuticals Limited | 4.36% | 3.76% |
| Max Healthcare Institute Limited | 4.62% | 3.71% |
| Lupin Limited | 3.24% | 3.14% |
| Fortis Healthcare Limited | 2.90% | 1.95% |
| Alkem Laboratories Limited | 1.92% | 2.36% |
| Aster DM Quality Care Limited | 1.22% | 1.67% |
| Sai Life Sciences Limited | 1.21% | 2.60% |
| Acutaas Chemicals Limited | 1.00% | 1.95% |
| Ajanta Pharma Limited | 0.94% | 1.63% |
| Dr. Lal Path Labs Limited | 0.92% | 1.76% |
| IPCA Laboratories Limited | 1.69% | 0.91% |
| Abbott India Limited | 0.81% | 5.94% |
| Mankind Pharma Limited | 1.64% | 0.77% |
| Anthem Biosciences Limited | 0.77% | 2.57% |
| GlaxoSmithKline Pharmaceuticals Limited | 0.76% | 0.76% |
| Biocon Limited | 1.77% | 0.69% |
| Syngene International Limited | 0.47% | 2.85% |
| Natco Pharma Limited | 0.47% | 1.51% |
| Rainbow Childrens Medicare Limited | 0.44% | 4.30% |
| Pfizer Limited | 0.43% | 2.50% |
| Procter & Gamble Health Limited | 0.28% | 2.75% |
| Healthcare Global Enterprises Limited | 0.24% | 5.92% |
| Dr Agarwals Health Care Limited | 0.24% | 0.68% |
| Sanofi Consumer Healthcare India Limited | 0.17% | 0.57% |
| FDC Limited | 0.10% | 2.24% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 53.9% means 53.9% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Bandhan BSE Healthcare Index Fund
| Security | % of fund |
|---|---|
| Laurus Labs Limited | 4.48% |
| Aurobindo Pharma Limited | 2.89% |
| Glenmark Pharmaceuticals Limited | 2.28% |
| Zydus Lifesciences Limited | 1.79% |
| Gland Pharma Limited | 1.40% |
Largest holdings only in Tata India Pharma & Healthcare Fund
| Security | % of fund |
|---|---|
| BAYER CROPSCIENCE LTD | 2.96% |
| PI INDUSTRIES LTD | 2.59% |
| SUMITOMO CHEMICAL INDIA LTD | 1.38% |
| GILLETTE INDIA LTD | 1.23% |
| NAVIN FLUORINE INTERNATIONAL LTD | 1.18% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Bandhan BSE Healthcare Index | Tata India Pharma & Healthcare |
|---|---|---|
| Equity | 100.1% | 99.7% |
| Debt | 0.0% | 0.0% |
| Cash and others | -0.1% | 0.3% |
Market cap of stocks
| Market cap | Bandhan BSE Healthcare Index | Tata India Pharma & Healthcare |
|---|---|---|
| Large Cap | 35.0% | 26.0% |
| Mid Cap | 38.9% | 33.9% |
| Small Cap | 25.9% | 37.0% |
| Not on AMFI's list | 0.3% | 2.9% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Bandhan BSE Healthcare Index | Tata India Pharma & Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 77.1% | 60.6% |
| Healthcare Services | 22.5% | 27.8% |
| Fertilizers & Agrochemicals | 0.0% | 6.9% |
| Chemicals & Petrochemicals | 0.0% | 2.6% |
| Personal Products | 0.0% | 1.2% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Bandhan BSE Healthcare Index vs Tata India Pharma & Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Bandhan BSE Healthcare Index Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.34% | 1.10% |
| Base expense ratio (Direct) | 0.19% | 0.64% |
| Total expense ratio (Regular) | 1.15% | 2.42% |
| Base expense ratio (Regular) | 0.88% | 1.82% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Tata India Pharma & Healthcare with
- Tata India Pharma & Healthcare vs Nippon India Taiwan Equity
- Tata India Pharma & Healthcare vs HDFC Defence
- Tata India Pharma & Healthcare vs HDFC Pharma and Healthcare
- Tata India Pharma & Healthcare vs SBI Healthcare Opportunities
- Tata India Pharma & Healthcare vs Aditya Birla Sun Life International Equity
Bandhan BSE Healthcare Index Fund vs Tata India Pharma & Healthcare Fund: Frequently Asked Questions
What is the difference between Bandhan BSE Healthcare Index Fund and Tata India Pharma & Healthcare Fund?
Bandhan BSE Healthcare Index Fund is an Index fund, Tata India Pharma & Healthcare Fund is a Thematic fund, run by Bandhan Mutual Fund and Tata Mutual Fund. Their portfolios overlap 53.9%. Bandhan BSE Healthcare Index Fund charges 0.34% a year and Tata India Pharma & Healthcare Fund 1.10%.
Which has given higher returns, Bandhan BSE Healthcare Index Fund or Tata India Pharma & Healthcare Fund?
Over 1 year: Bandhan BSE Healthcare Index Fund +11.96%, Tata India Pharma & Healthcare Fund +4.28%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Bandhan BSE Healthcare Index Fund or Tata India Pharma & Healthcare Fund?
Bandhan BSE Healthcare Index Fund charges less: 0.34% a year against 1.10%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Bandhan BSE Healthcare Index Fund and Tata India Pharma & Healthcare Fund overlap?
53.9%. They hold 30 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, Bandhan BSE Healthcare Index Fund or Tata India Pharma & Healthcare Fund?
On SEBI's riskometer, Bandhan BSE Healthcare Index Fund is rated Very High and Tata India Pharma & Healthcare Fund Very High. Over 1 years, the standard deviation of daily returns was 13.61% and 11.99% a year.
Can I invest in both Bandhan BSE Healthcare Index Fund and Tata India Pharma & Healthcare Fund?
Yes. 53.9% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Bandhan BSE Healthcare Index Fund and Tata India Pharma & Healthcare Fund?
Bandhan BSE Healthcare Index Fund: Abhishek Jain. Tata India Pharma & Healthcare Fund: Rajat Srivastava.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.